SCHEMBL377065

SCHEMBL377065

Fc1cc(CBr)c(F)cc1Br

nearest known ligand 0.59

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 8/20 0.41
KDM1B Q8NB78 5/20 0.41
KCNH2 Q12809 4/20 0.41
DPP4 P27487 1/20 0.33
IDO1 P14902 1/20 0.30
AGXT P21549 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29545980 1.00 KDM1A (0.41) KDM1AKDM1BKCNH2DPP4IDO1
SCHEMBL1262764 0.90 DPP4 (0.33) KDM1AKDM1BKCNH2DPP4IDO1
SCHEMBL30441973 0.90 DPP4 (0.33) KDM1AKDM1BKCNH2DPP4IDO1
SCHEMBL21521510 0.87 KDM1A (0.38) KDM1AKDM1BKCNH2DPP4
SCHEMBL18226969 0.87 DPP4 (0.39) DPP4IDO1AGXT
SCHEMBL2528520 0.85 KDM1A (0.36) KDM1AKDM1BKCNH2
SCHEMBL16860902 0.85 DPP4 (0.33) DPP4
SCHEMBL3366165 0.82 DPP4 (0.34) KDM1AKDM1BKCNH2DPP4
SCHEMBL344590 0.81 DPP4 (0.46) DPP4
SCHEMBL24357635 0.79 KDM1A (0.32) KDM1AKDM1BDPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612360-B2 Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof SANOFI (FR) 2026-04-28 US disclosed
US-12595230-B2 Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof SANOFI (FR) 2026-04-07 US disclosed
US-20260062420-A1 NOVEL DPP1 INHIBITORS AND USES THEREOF INSMED INC (US) 2026-03-05 US disclosed
EP-4561565-A2 NOVEL DPP1 INHIBITORS AND USES THEREOF Insmed Incorporated (US) 2025-06-04 EP disclosed
WO-2025106910-A1 DEGRADER MOLECULES TARGETING ANDROGEN RECEPTOR FLARE THERAPEUTICS INC. (US) 2025-05-22 WO disclosed
EP-4228757-B1 SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF SANOFI SA (FR) 2024-08-14 EP disclosed
EP-4228758-B1 SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF SANOFI SA (FR) 2024-07-24 EP disclosed
US-20240239816-A1 BORONO-PHENYLALANINE DERIVATIVE STELLA PHARMA CORPORATION (JP) 2024-07-18 US disclosed
EP-4361159-A1 BORONO-PHENYLALANINE DERIVATIVE Stella Pharma Corporation (JP) 2024-05-01 EP disclosed
US-20240101512-A1 Substituted 6,7-Dihydro-5H-Benzo[7]Annulene Compounds and Their Derivatives, Processes for Their Preparation and Therapeutic Uses Thereof SANOFI (FR) 2024-03-28 US disclosed
CN-1861077-A Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes MERCK & CO INC (US) 2006-11-15 CN disclosed
US-7125873-B2 Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes MERCK & CO., INC. (US) 2006-10-24 US disclosed
EP-1412357-B1 BETA-AMINO TETRAHYDROIMIDAZO(1,2-A)PYRAZINES AND TETRAHYDROTRIAZOLO(4,3-A)PYRAZINES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES MERCK & CO INC (US) 2006-03-22 EP disclosed
EP-1625847-A1 Pharmaceutical composition comprising a tetrahydrotriazolo[4,3-a]pyrazine Merck & Co., Inc. (US) 2006-02-15 EP disclosed
US-20040167133-A1 Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4,3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes MERCK SHARP & DOHME LLC 2004-08-26 US disclosed
CN-1524082-A Beta-aminotetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotriazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 2004-08-25 CN disclosed
EP-1412357-A1 BETA-AMINO TETRAHYDROIMIDAZO(1,2-A)PYRAZINES AND TETRAHYDROTRIAZOLO(4,3-A)PYRAZINES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES Merck & Co., Inc. (US) 2004-04-28 EP disclosed
US-6699871-B2 SUCH AS 7-((3R)-3-AMINO-4-(3,4-DIFLUOROPHENYL)BUTANOYL)-2-(TRIFLUOROMETHYL)-5,6,7,8 -TETRAHYDROIMIDAZO(1,2-A)PYRAZINE DIHYDROCHLORIDE FOR TREATMENT OF INSULIN RESISTANCE DISORDERS MERCK & CO., INC. 2004-03-02 US disclosed
US-20030100563-A1 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes SALZUFER HOLDING INC., AS ADMINISTRATIVE AGENT 2003-05-29 US disclosed
WO-2003004498-A1 BETA-AMINO TETRAHYDROIMIDAZO (1, 2-A) PYRAZINES AND TETRAHYDROTRIOAZOLO (4, 3-A) PYRAZINES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES MERCK & CO., INC. (US) 2003-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12612360-B2 Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof ESRRA, FSHR, GPER1 KDM1A 1203/4885KDM1B 1220/4885KCNH2 1488/4885
US-20240101512-A1 Substituted 6,7-Dihydro-5H-Benzo[7]Annulene Compounds and Their Derivatives, Processes for Their Preparation and Therapeutic Uses Thereof CYP19A1, FSHR, GPER1 KDM1A 902/4885KDM1B 1183/4885KCNH2 717/4885
US-20040167133-A1 Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4,3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes DPP4, DPP3, DPP7 KDM1A 2107/4885KDM1B 2187/4885KCNH2 2301/4885
US-20240239816-A1 BORONO-PHENYLALANINE DERIVATIVE SLC7A1, SLC1A5, LATS2 KDM1A 2483/4885KDM1B 1882/4885KCNH2 4258/4885
US-20030100563-A1 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes DPP4, DPP3, DPP7 KDM1A 2806/4885KDM1B 2091/4885KCNH2 2900/4885
US-12595230-B2 Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof FSHR, CYP19A1, GPER1 KDM1A 1528/4885KDM1B 1712/4885KCNH2 1044/4885
US-20260062420-A1 NOVEL DPP1 INHIBITORS AND USES THEREOF DPP4, DPP3, DPP7 KDM1A 672/4885KDM1B 917/4885KCNH2 2268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.